Clinical significance of serum S100 in metastatic malignant melanoma

Guo, Hua; Stoffel‐Wagner, Birgit; Bierwirth, T.; Mezger, J.; Klingmüller, Dietrich

doi:10.1016/0959-8049(95)00087-9

Cited by 113 publications

(73 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum S 100 in the sera of melanoma patients has been thought to be, in part, derived from tumour tissue, as evidenced by the immunohistochemical detection of the S100 protein in malignant melanoma tissue (Gaynor et al, 1981). More recently, in a preliminary analysis, serum S100 was shown to correlate with the clinical stage of the tumour (Guo et al, 1995).…”

Section: Resultsmentioning

confidence: 99%

“…Expression of S100 is found in malignant melanoma, and elevated serum levels of S100 have been described in metastatic malignant melanoma (Gaynor et al, 1981;Fagnart et al, 1988). Previously, increased serum S100 has been identified as a marker of disease progression in metastatic malignant melanoma (Guo et al, 1995). Therefore, serum S100 might be a useful adjunct in the clinical staging and monitoring of metastatic malignant melanoma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Elevated serum levels of S100 and survival in metastatic malignant melanoma

Buer

Probst²,

Franzke³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Elevated serum levels of S100 and survival in metastatic malignant melanoma

Buer

Probst²,

Franzke³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Later, S-100B was found to be a serological tumor marker for melanoma and seemed to be mostly increased in stage III and IV [109,112]. According to the literature to date,…”

Section: S-100bmentioning

confidence: 99%

“…Successful treatment with lymph node dissection, chemotherapy or immuno therapy was associated with decreased S-100B concentrations, whereas increased concentrations were an expression of disease progression [112,116,117]. Recently it was reported by several studies that S-100B can be used as a prognostic marker for disease-free survival and overall survival directly after therapeutic lymph node dissection in stage III melanoma [118][119][120][121].…”

Section: Reviewmentioning

confidence: 99%

Optimal follow-up for melanoma

Speijers

Francken

Hoekstra-Weebers

et al. 2010

Expert Review of Dermatology

View full text Add to dashboard Cite

“…Serum S-100B is a useful tumormarker in melanoma patients, indicating the presence of distant metastases and reflecting the tumor burden. In addition, S-100B has prognostic implications (18)(19)(20)(21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy response assessment in stage IV melanoma patients—comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B

Strobel

Dummer

Steinert

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

PURPOSE: This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients. METHODS: In 25 patients with stage IV melanoma, FDG-PET/CT and S-100B after 2-3 months (three cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B. Retrospectively, the response was correlated with the outcome. In patients with clinical suspicion for brain metastases, MRI or CCT was performed. RESULTS: There was agreement between FDG-PET/CT and CT regarding response to chemotherapy in all patients. There was a clear trend to a longer OS of PET/CT responders (n = 10) compared with PET/CT non-responders (n = 15; p = 0.072) with remarkably better 1-year OS of 80% compared to 40% (p = 0.048). There was a significant longer PFS of PET/CT responders compared with PET/CT non-responders (p = 0.002). S-100B was normal at baseline in eight of 22 patients where it was available. Chemotherapy response assessment with S-100B failed to show correlation with OS or PFS. Eleven patients developed brain metastases during treatment, first detected by PET/CT in two and by MRI or CCT in nine of 11 patients. Appearance of brain metastases was associated with a poor survival. CONCLUSIONS: 18F-FDG-PET/CT and CT alone are equally suitable for chemotherapy response assessment in melanoma patients and clearly superior to S-100B. PET/CT responders have better early survival, but this is shortlived due to late therapy failure-often with brain recurrence. Additional brain MRI for therapy response assessment in such high-risk patients is mandatory to detect brain metastases missed by PET/CT. Chemotherapy Response Assessment in MethodsIn 25 patients with stage IV melanoma FDG-PET/CT and S-100B after 2-3 months (3 cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B.Retrospectively, the response was correlated with the outcome. In patients with clinical suspicion for brain metastases MRI or CCT was performed. ResultsThere was agreement between FDG-PET/CT and CT regarding response to chemotherapy in all patients. There was a clear trend to a longer OS of PET/CTresponders (n=10) compared with PET/CT non-responders (n=15) (p=.072) with remarkably better 1-year OS of 80% compared to 40% (p=.048). There was a significant longer PFS of PET/CT-responders compared with PET/CT nonresponders (p=.002). S-100B was normal at baseline in 8 of 22 patients where it was available. Chemotherapy response assessment with S -100B failed to show correlation with OS or PFS. 11 patients developed brain metastases during treatment, first detected by PET/CT in 2 and by MRI or CCT in 9 of 11 patients.Appearance of brain metastases was associated with a poor survival.

show abstract

Clinical significance of serum S100 in metastatic malignant melanoma

Cited by 113 publications

References 15 publications

Elevated serum levels of S100 and survival in metastatic malignant melanoma

Elevated serum levels of S100 and survival in metastatic malignant melanoma

Optimal follow-up for melanoma

Chemotherapy response assessment in stage IV melanoma patients—comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B

Contact Info

Product

Resources

About